Syndax Pharmaceuticals announced that its Phase 2 trial for axatilimab in treating idiopathic pulmonary fibrosis failed to meet its primary endpoint, leading to a 2.59% drop in its stock price. Following this, Pomerantz LLP launched an investigation into whether Syndax and its executives engaged in securities fraud or other unlawful practices. Investors affected by this are encouraged to contact the law firm for potential class action participation. This legal scrutiny could impact Syndax's future operations and investor confidence.
The story concerns Syndax Pharmaceuticals and related investor legal actions. For readers following the Health sector, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: out of 150 priced US Health-sector stocks, 42 rose and 108 fell. Notable movers include CLPT at USD 8.61 with a -6.11% change, TNGX at USD 24.24 with a -5.79% change and balanced buy/sell orders, and BFLY at USD 6.73 with a -5.74% change.
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
